MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
AcelRx Pharmaceuticals Net Income 2011-2025 | ACRX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income AcelRx Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13 M | -18.4 M | 47.8 M | -35.1 M | -40.4 M | -53.2 M | -47.1 M | -51.5 M | -43.2 M | -24.4 M | -33.4 M | -23.4 M | -33.4 M | -20.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.8 M | -53.2 M | -27.8 M |
Quarterly Net Income AcelRx Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.44 M | -3.49 M | -2.59 M | - | -3.35 M | -3.83 M | -3.95 M | - | -1.36 M | -4.37 M | -8.15 M | - | -6.75 M | 70.7 M | -8.67 M | - | -8.38 M | -9.85 M | -8.96 M | - | -8.93 M | -6.61 M | -15.9 M | -14.4 M | -12.7 M | -12.4 M | -13.7 M | -12.6 M | -12.5 M | -10.5 M | -11.6 M | -9.88 M | -13 M | -13.1 M | -15.6 M | -9.68 M | -11.4 M | -11.1 M | -11 M | -10.5 M | 5.07 M | -8.9 M | -10 M | -13.8 M | 671 K | -10.6 M | -9.63 M | 17.8 M | -11 M | -17.4 M | -12.8 M | -10.5 M | -8.58 M | -7.19 M | -7.06 M | -6.37 M | -5.76 M | -4.76 M | -3.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70.7 M | -17.4 M | -6.83 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
-598 M | $ 1.74 | - | $ 187 M |  Canada |
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-332 M | $ 0.76 | - | $ 54 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
-73.1 M | $ 3.27 | - | $ 1.72 B | Canada |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-695 M | $ 5.4 | - | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | USA |
 |
OrganiGram Holdings
OGI
|
-131 M | $ 1.92 | - | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
861 K | $ 4.82 | - | $ 635 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-760 M | $ 11.41 | - | $ 584 M | USA |
 |
Pacira BioSciences
PCRX
|
-99.6 M | $ 26.29 | - | $ 1.22 B | USA |
 |
Evoke Pharma
EVOK
|
-7.79 M | $ 10.95 | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Rockwell Medical
RMTI
|
-8.44 M | $ 0.92 | - | $ 21.5 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | $ 21.36 | - | $ 2.03 B |  France |
 |
Solid Biosciences
SLDB
|
-125 M | $ 5.87 | - | $ 240 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 3.59 | - | $ 4.46 M | USA |
 |
Evolus
EOLS
|
-50.4 M | $ 7.04 | 1.88 % | $ 437 M | USA |
 |
Harrow Health
HROW
|
-24.4 M | $ 47.06 | - | $ 1.53 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.74 M | $ 1.55 | -0.38 % | $ 27.1 M |  China |
 |
Veru
VERU
|
-37.8 M | $ 2.42 | - | $ 326 M | USA |
 |
Bausch Health Companies
BHC
|
-592 M | $ 6.92 | - | $ 2.53 B | Canada |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 2.53 | 1.61 % | $ 35.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
13.7 M | - | - | $ 193 M | Canada |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-98.8 M | $ 4.06 | - | $ 122 M | USA |
 |
Jupiter Wellness
JUPW
|
-49.4 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-172 M | $ 13.14 | - | $ 1.81 B | USA |
 |
ProPhase Labs
PRPH
|
18.5 M | $ 0.11 | - | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-230 M | $ 2.21 | - | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-153 K | $ 1.2 | - | $ 5.18 M | USA |
 |
SCYNEXIS
SCYX
|
67 M | $ 0.65 | - | $ 31.1 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.45 B | $ 12.15 | - | $ 7.51 B | Canada |
 |
TherapeuticsMD
TXMD
|
-10.3 M | $ 1.75 | - | $ 18.3 M | USA |
 |
Zomedica Corp.
ZOM
|
-34.5 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
2.08 B | $ 11.65 | - | $ 14.1 B | USA |